Everything below concerns REV-ERB. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
=== Tip designs === Syringes come with a number of designs for the area in which the blade locks to the syringe body. Perhaps the most well known of these is the Luer lock, which simply twists the two together. Bodies featuring a small, plain connection are known as slip tips and are useful for when the syringe is being connected to something not featuring a screw lock mechanism. Similar to this is the catheter tip, which is essentially a slip tip but longer and tapered, making it good for pushing into things where there the plastic taper can form a tight seal. These can also be used for rinsing out wounds or large abscesses in veterinary use. There is also an eccentric tip, where the nozzle at the end of the syringe is not in the centre of the syringe but at the side. This causes the blade attached to the syringe to lie almost in line with the walls of the syringe itself and they are used when the blade needs to get very close to parallel with the skin (when injecting into a surface vein or artery for example).
==== Lamellipodia ==== A meshwork of actin filaments marks the forward edge of a moving cell, and the polymerization of new actin filaments pushes the cell membrane forward in protrusions called lamellipodia. These membrane protrusions then attach to the substrate, forming structures known as focal adhesions that connect to the actin network. Once attached, the rear of the cell body contracts squeezing its contents forward past the adhesion point. Once the adhesion point has moved to the rear of the cell, the cell disassembles it, allowing the rear of the cell to move forward.
==== In animals ==== PABA has been referred to historically as "vitamin Bx", but plays no direct role in animal cells and is hence no longer recognized as a vitamin. Animals (including humans) are unable to use PABA in any way and so require folate from dietary sources such as green leafy vegetables. PABA can play a role in the supply of folate to an animal via its microbiome; this is best demonstrated in the worm C. elegans, in which addition of PABA could increase folate production by resident E. coli and correct for deficiencies. The C. elegans folate transporter only works with the reduced form (tetrahydrofolate, THF and derivatives such as folinic acid), not regular folic acid. Any folic acid from the environment is only usable following spontaneous breakdown to PABA-glu, which E. coli uses to make THF. In contrast, humans can directly use oxidized folates thanks to the proton-coupled folate transporter and have no need for this detour; this "recycling" of PABA-glu would, at best, compensate for folate degradation. The above do not seem to apply in normal mammals, however. Despite detection of gut-produced folate being incorporated into mammals, ex vivo folate synthesis capacity of fecal bacteria have no correlation with the folate status of their donors. Furthermore, comparison with germ-free animals show that under a chow diet, the mouse microbiome is a net consumer of folate. The caveat is that the mouse chow is more folate-rich than typical human diets and may be encouraging a shift towards a folate-consuming microbiome.
Sources: en.wikipedia.org
A wound of less than 10 mm in diameter can be managed either by primary intention healing (suturing) or by secondary intention healing (re-epithelialisation). A wound measuring 10–15 mm in diameter can be reconstructed with a single-stage modified bilobed flap, because it best matches the skin color and the skin texture of the wounded aesthetic subunit. Although not every scar can be hidden at the margins of the aesthetic nasal subunits concerned, the superior scarring ability of those nasal skin areas minimizes such an histologic disadvantage. In a patient whose basal-cell carcinoma was excised with Mohs surgery, the scar of the nasal reconstruction (an 11 mm full-thickness, laterally based, bilobed-flap applied down to the bone and the cartilage), was hidden by aligning the axis of the second lobe to and emplacing the skin graft at the junction of the nasal dorsum and the lateral wall of the nose. A wound greater than 15 mm in diameter can be corrected with a paramedian forehead flap, which will reconstruct either the entire nasal dorsum or the lateral wall of the nose, as required. The surgical management of such wounds (< 15 mm dia.) usually requires enlarging the wound as necessary, in order for the skin graft to comprehend the entire aesthetic subunit being corrected. Moreover, if the wound comprehends the dorsum and the lateral wall of the nose, then a cheek-advancement skin flap is the applicable correction for replacing the lateral nasal skin up to its junction with the dorsum; afterwards, a paramedian forehead flap is applied to resurface the nasal dorsum.
Mixue Ice Cream & Tea (Chinese: 蜜雪冰城; pinyin: Mìxuě Bīngchéng; lit. 'honey snow ice city', ME-shweh) is a Chinese multinational restaurant chain specializing in ice cream and tea-based drinks. It was founded in 1997 in Zhengzhou by Zhang Hongchao. At the end of 2025, it operated almost 60,000 stores in China and overseas, making it the world's largest food-service chain by number of stores. Most locations are franchised and the company generates a large share of its revenue by supplying ingredients, equipment, and packaging to franchisees. Its menu emphasizes low-priced items such as soft-serve ice cream and milk tea. Mixue's parent company, Mixue Group, is listed on the Hong Kong Stock Exchange. The initial public offering raised about HK$3.45 billion (approximately US$444 million at the time) and the shares rose by about 40–47% on the first day of trading.
There is much criticism indicating that the Nova classification refers to formulation and additives while processing levels must relate to unit operations and food processing. Food processing categories with typical processes are given in Table 1.
=== Basal rate determination === Basal insulin requirements will vary between individuals and periods of the day. The basal rate for a particular time period is determined by fasting while periodically evaluating the blood sugar level. Neither food nor bolus insulin must be taken for 4 hours before or during the evaluation period. If the blood sugar level changes dramatically during evaluation, then the basal rate can be adjusted to increase or decrease insulin delivery to keep the blood sugar level approximately steady. For instance, to determine an individual's morning basal requirement, they must skip breakfast. On waking, they would test their blood glucose level periodically until lunch. Changes in blood glucose level are compensated with adjustments in the morning basal rate. The process is repeated over several days, varying the fasting period, until a 24-hour basal profile has been built up which keeps fasting blood sugar levels relatively steady. Once the basal rate is matched to the fasting basal insulin need, the pump user will then gain the flexibility to skip or postpone meals such as sleeping late on the weekends or working overtime on a weekday. Many factors can change insulin requirements and require an adjustment to the basal rate:
Sources: en.wikipedia.org
RYB (an abbreviation of red–yellow–blue) is a subtractive color model used in art and applied design in which red, yellow, and blue pigments are considered primary colors. Under traditional color theory, this set of primary colors was advocated by Moses Harris, Michel Eugène Chevreul, Johannes Itten and Josef Albers, and applied by countless artists and designers. The RYB color model underpinned the color curriculum of the Bauhaus, Ulm School of Design and numerous art and design schools that were influenced by the Bauhaus, including the IIT Institute of Design (founded as the New Bauhaus), Black Mountain College, Design Department Yale University, the Shillito Design School, Sydney, and Parsons School of Design, New York. In this context, the term primary color refers to three exemplar colors (red, yellow, and blue) as opposed to specific pigments. As illustrated, in the RYB color model, red, yellow, and blue are intermixed to create secondary color segments of orange, green, and purple. This set of primary colors emerged at a time when access to a large range of pigments was limited by availability and cost, and it encouraged artists and designers to explore the many diverse colors through mixing and intermixing a limited range of pigment colors. In art and design education, gray, red, yellow, and blue pigments were usually augmented with white and black pigments, enabling the creation of a larger gamut of colors and details including tints and shades.
Implement specific measures to detect and deter money laundering and the financing of terrorist activities and to facilitate the investigation and prosecution of money laundering and terrorist financing offences including: Mandatory report requirement of suspicious financial transaction, large electronic fund transfers, and all large cash transactions, establishment of record keeping and client identification requirements for financial service providers and other persons that engage in businesses, professions or activities that are susceptible to being used for money laundering and the financing of terrorist activities. Fulfill Armenia's commitments to participate in the global fight against money laundering and terrorist financing. Towards this end, a special agency called Interagency Task Force 4 was created, which is responsible for the continual effective and cooperative activity in the sphere of fraudulence connected with money laundering, credit cards as well as terrorist financing in Armenia. To respond to the threat posed by organized criminals and terrorists by providing law enforcement officials with the information they need to deprive criminals and terrorists of the proceeds of their criminal activities and funds to support terrorist activities, while ensuring that appropriate safeguards are put in place to protect privacy of persons with respect to personal information.
Art forensics concerns the art authentication cases to help research the work's authenticity. Art authentication methods are used to detect and identify forgery, faking and copying of art works, e.g. paintings. Bloodstain pattern analysis is the scientific examination of blood spatter patterns found at a crime scene to reconstruct the events of the crime. Comparative forensics is the application of visual comparison techniques to verify similarity of physical evidence. This includes fingerprint analysis, toolmark analysis, and ballistic analysis. Computational forensics concerns the development of algorithms and software to assist forensic examination. Criminalistics is the application of various sciences to answer questions relating to examination and comparison of biological evidence, trace evidence, impression evidence (such as fingerprints, footwear impressions, and tire tracks), controlled substances, ballistics, firearm and toolmark examination, and other evidence in criminal investigations. In typical circumstances, evidence is processed in a crime lab. Digital forensics is the application of proven scientific methods and techniques in order to recover data from electronic / digital media. Digital Forensic specialists work in the field as well as in the lab. Ear print analysis is used as a means of forensic identification intended as an identification tool similar to fingerprinting. An earprint is a two-dimensional reproduction of the parts of the outer ear that have touched a specific surface (most commonly the helix, antihelix, tragus and antitragus).
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.